Therapeutic activity does not respect kingdom boundaries. NeuroBotanica models, predicts, and validates cross-kingdom molecular interactions computationally — before any laboratory synthesis.
Polysaccharides from marine organisms, fungal cell walls, and plant mucilages share structural and immunological properties that interact synergistically with cannabinoids, terpenes, and alkaloids. No competitor has modeled this interaction space computationally.
Our platform is built to model, predict, and validate these cross-kingdom interactions using a Message Passing Neural Network (MPNN) with 98.11% GenomePath prediction accuracy — generating 21,000+ novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential.
This is a predictive systems biology approach, not a chemical lookup table.
Each kingdom contributes a distinct compound class. Cross-kingdom synergy is where the therapeutic innovation happens.
THC, CBD, CBN, CBG, CBDV and 12 additional cannabinoids + 4 active metabolites. 16 neuropsychiatric conditions, pain, epilepsy, oncology support.
Fucoidan, carrageenan, ulvan from seaweed. Immunomodulation, oncology support, anti-inflammatory. TLR2/4 receptor modeling.
Beta-glucans, hericenones, cordycepin, lentinan. Neuroprotection, immune enhancement, cognitive support. Dectin-1 receptor modeling.
Galactomannans, rhamnogalacturonans, pectins. Glycemic control, gut health, topical therapeutics. Ayurvedic and European TK validation.
Message Passing Neural Network models molecular interactions across compound classes. 98.11% accuracy on GenomePath TK→Genomic validation. Predicts synergy before synthesis.
Generates 21,000+ novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential across all four kingdoms.
EthnoPath module integrates validated traditional knowledge into compound discovery pathways. FPIC-governed, consent-logged, and attribution-tracked via VeriTrad.
EquiPath integration detects and corrects demographic bias in all predictions. 96% accuracy. Ensures recommendations work across populations — not just overrepresented groups.
RegPath module maps each compound to FDA and DSHEA pathways. GRAS notifications, NDI submissions, clinical trial design — regulatory readiness built into the platform.
Every recommendation is ranked by evidence quality — meta-analysis, RCT, cohort, in vitro, traditional use. Transparent, reproducible, auditable at every step.
Dispensaries, researchers, academic institutions, and community organizations. There is a structured partnership pathway for each.